BIP
TAK icon

Brandes Investment Partners’s Takeda Pharmaceutical TAK Stock Holding History

Brandes Investment Partners’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$72.8M Buy
4,539,347
+108,705
+2% +$1.8M 0.51% 80
2026
Q1 		$82.1M Buy
4,430,642
+548,760
+14% +$9.63M 0.58% 61
2025
Q4 		$60.5M Sell
3,881,882
-49,921
-1% -$714K 0.46% 71
2025
Q3 		$57.6M Buy
3,931,803
+219,525
+6% +$3.26M 0.46% 74
2025
Q2 		$57.4M Buy
3,712,278
+208,136
+6% +$3.08M 0.52% 67
2025
Q1 		$52.1M Buy
3,504,142
+464,557
+15% +$6.51M 0.53% 66
2024
Q4 		$40.2M Sell
3,039,585
-192,019
-6% -$2.64M 0.45% 70
2024
Q3 		$46M Buy
3,231,604
+596,577
+23% +$8.46M 0.52% 65
2024
Q2 		$34M Sell
2,635,027
-267,480
-9% -$3.54M 0.42% 69
2024
Q1 		$40.3M Buy
2,902,507
+251,242
+9% +$3.65M 0.52% 62
2023
Q4 		$37.8M Buy
2,651,265
+849,229
+47% +$12M 0.57% 59
2023
Q3 		$27.9M Buy
1,802,036
+36,717
+2% +$568K 0.54% 59
2023
Q2 		$27.7M Sell
1,765,319
-52,653
-3% -$863K 0.56% 55
2023
Q1 		$30M Buy
1,817,972
+1,699,552
+1,435% +$27.1M 0.64% 49
2022
Q4 		$1.85M Sell
118,420
-1,752,623
-94% -$24.5M 0.05% 95
2022
Q3 		$24.3M Sell
1,871,043
-151,504
-7% -$2.11M 0.63% 45
2022
Q2 		$28.4M Sell
2,022,547
-87,299
-4% -$1.25M 0.69% 44
2022
Q1 		$30.2M Buy
2,109,846
+360,083
+21% +$5.29M 0.65% 45
2021
Q4 		$23.9M Sell
1,749,763
-266,061
-13% -$3.73M 0.52% 56
2021
Q3 		$33M Sell
2,015,824
-66,411
-3% -$1.11M 0.72% 48
2021
Q2 		$35M Buy
2,082,235
+321,387
+18% +$5.47M 0.78% 43
2021
Q1 		$32.3M Buy
1,760,848
+97,767
+6% +$1.76M 0.76% 44
2020
Q4 		$30.2M Buy
1,663,081
+208,042
+14% +$3.65M 0.78% 46
2020
Q3 		$26M Sell
1,455,039
-215,770
-13% -$3.93M 0.9% 41
2020
Q2 		$30M Sell
1,670,809
-127,430
-7% -$2.29M 0.91% 41
2020
Q1 		$27.3M Buy
1,798,239
+84,890
+5% +$1.54M 0.96% 39
2019
Q4 		$33.8M Sell
1,713,349
-129,886
-7% -$2.48M 0.8% 41
2019
Q3 		$31.7M Buy
1,843,235
+499,819
+37% +$8.64M 0.82% 44
2019
Q2 		$23.8M Sell
1,343,416
-133,599
-9% -$2.43M 0.53% 55
2019
Q1 		$30.1M Buy
1,477,015
+463,133
+46% +$9.32M 0.7% 47
2018
Q4 		$17.1M Buy
+1,013,882
New +$17.1M 0.43% 61

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Brandes Investment Partners's TAK Position: Q2 2026 in Review

Brandes Investment Partners increased its Takeda Pharmaceutical (TAK) stake by 2.5% in Q2 2026, buying an estimated $1.8M and bringing the position to 4,539,347 shares worth $72.8M. The position accounts for 0.51% of the portfolio, ranked #80.

Brandes Investment Partners first reported a position in TAK in Q4 2018 and has held it in 31 quarters since. The position peaked at $82.1M in Q1 2026. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

  • Brandes Investment Partners held 4,539,347 shares of Takeda Pharmaceutical worth $72.8M as of Q2 2026.
  • Brandes Investment Partners bought 108,705 Takeda Pharmaceutical shares in Q2 2026, an estimated $1.8M.
  • Takeda Pharmaceutical made up 0.51% of Brandes Investment Partners's portfolio in Q2 2026, its #80 holding.
  • Brandes Investment Partners first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 31 quarters since.
  • Brandes Investment Partners's Takeda Pharmaceutical position peaked at $82.1M in Q1 2026.
  • 378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Brandes Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.